Genetic Immunity out-licenses HIV vaccine tech to Pharmadis in Russia

18 December 2018

One of Russia’s largest pharma distributors has in-licensed trans-dermally delivered pDNA-based therapeutic HIV vaccine technology from Genetic Immunity, a clinical stage biotech company.

Pharmadis has acquired the rights to market the DermaVir technology in Russia and the Commonwealth of Independent States.

As part of the agreement, to qualify for Russian marketing approval, a new clinical study involving 200 patients will be conducted in Moscow. This is expected to be completed in 2020 and will be paid for by Pharmadis, as will any subsequent filing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK